Abstract
Propose: This study was done to reduce atrophic vaginitis. Aim: This study aimed to compare the effects of Vagiheal Gel and Estromarin in reducing atrophic vaginitis
Methods: This study was a randomized clinical trial with a parallel design. 70 postmenopausal women who had dyspareunia and were referred to the health clinics of Arak, Iran were included in this study. Patients were assigned to one of the 2 groups of Vagiheal or Estromarin. The patients in the Estromarin group were provided with 0.625 mg/g vaginal cream for intravaginal use 2.5 grams for 21 nights. After one week of medicinal rest, they were prescribed 2.5 grams of intravaginal cream for another 21 nights, and then, one week of medicinal rest was considered. The patients in the Vagiheal group were prescribed 2.5 grams of Vagiheal Gel by inserting the applicator into the vagina when sleeping for 7 consecutive nights, then as a maintenance treatment for 2 times a week for 2 months. The severity of the symptoms was measured by a visual Analog scale(VAS) before, 2 weeks, 1 month, and 2 months after starting the program. The data were analyzed using T-test, Mann-Whitney, Chi-square, and Friedman test.
Results: The results of atrophic vaginitis follow-up processes showed that the mean of dryness, itching, and burning of the vagina in both groups significantly decreased after the intervention (p=0.01); however, the decrease of these symptoms in the dyspareunia group was more obvious in Vagiheal gel
Conclusion: It seems that Vagiheal gel is a suitable alternative to atrophic vaginitis treatment